Marc Chioda

Clinical Management of Adverse Events Associated with Lorlatinib

Todd M. Bauer, Enriqueta Felip, Benjamin Solomon et al. · The Oncologist · 2019 · 157 citations · Full text

Discovery of MK-7725, A Potent, Selective Bombesin Receptor Subtype-3 Agonist for the Treatment of Obesity

Harry R. Chobanian, Yan Guo, Ping Liu et al. · ACS Medicinal Chemistry Letters · 2012 · 61 citations · Full text

Consensus Recommendations for Management and Counseling of Adverse Events Associated With Lorlatinib: A Guide for Healthcare Practitioners

Mollie Lehner Reed, Aimee-Lauren S. Rosales, Marc Chioda et al. · Advances in Therapy · 2020 · 51 citations · Full text

Discovery of Benzodiazepine Sulfonamide-Based Bombesin Receptor Subtype 3 Agonists and Their Unusual Chirality

Ping Liu, Thomas J. Lanza, Marc Chioda et al. · ACS Medicinal Chemistry Letters · 2011 · 43 citations · Full text

Medicinal Chemistry, Pharmaceutical Chemistry, Biochemistry +14

Discovery of MK-4409, a Novel Oxazole FAAH Inhibitor for the Treatment of Inflammatory and Neuropathic Pain

Harry R. Chobanian, Yan Guo, Ping Liu et al. · ACS Medicinal Chemistry Letters · 2014 · 41 citations · Full text

Pain Medicine, High Throughput, Neuropathic Pain +16